
Renalytix AI plc RNLX
Quartalsbericht 2024-Q3
hinzugefügt 19.11.2024
Renalytix AI plc EV/EBITDA 2011-2026 | RNLX
EV/EBITDA Jährlich Renalytix AI plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -32.1 | -44.1 | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -32.1 | -44.1 | -38.1 |
EV/EBITDA anderer Aktien in der Diagnostik & Forschung
| Name | EV/EBITDA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
26.4 | $ 9.0 | 1.47 % | $ 600 M | ||
|
Brainsway Ltd.
BWAY
|
-43.6 | $ 13.99 | 2.49 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
-21.2 | $ 26.24 | 1.59 % | $ 729 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
22 | $ 154.17 | 1.45 % | $ 7.64 B | ||
|
DexCom
DXCM
|
39.5 | $ 68.54 | 3.32 % | $ 26.7 B | ||
|
CareDx, Inc
CDNA
|
-100 | $ 17.77 | 2.6 % | $ 947 M | ||
|
Guardant Health
GH
|
-28.8 | $ 88.16 | 1.12 % | $ 11.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-20.8 | $ 103.95 | 0.1 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
2.58 | $ 15.57 | 4.15 % | $ 471 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
-4.25 | $ 17.22 | -0.4 % | $ 2.23 B | ||
|
ICON Public Limited Company
ICLR
|
38 | $ 101.08 | 3.55 % | $ 8.34 B | ||
|
Anixa Biosciences
ANIX
|
-2.25 | $ 2.88 | 1.23 % | $ 93.5 K | ||
|
IQVIA Holdings
IQV
|
24.1 | $ 169.85 | 3.01 % | $ 29.2 B | ||
|
Danaher Corporation
DHR
|
20.1 | $ 195.65 | 2.23 % | $ 139 B | ||
|
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
70.5 | $ 121.72 | 2.04 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 198.39 | -0.28 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
27.4 | $ 113.9 | 1.85 % | $ 34.6 B | ||
|
BioNano Genomics
BNGO
|
-7.71 | $ 1.12 | 0.91 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
-1.05 | $ 9.28 | 10.24 % | $ 263 M | ||
|
NeoGenomics
NEO
|
-33.5 | $ 8.39 | 1.76 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
40.3 | $ 9.45 | 3.73 % | $ 2.05 B | ||
|
Lantheus Holdings
LNTH
|
-187 | $ 78.83 | 0.41 % | $ 5.32 B | ||
|
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
-23.8 | $ 1.41 | 3.68 % | $ 423 M | ||
|
Co-Diagnostics
CODX
|
3.62 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
30.7 | $ 458.61 | 1.1 % | $ 13.2 B | ||
|
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
827 | $ 1 220.43 | 1.77 % | $ 25.2 B | ||
|
Celcuity
CELC
|
-2.38 | $ 115.07 | 0.15 % | $ 4.54 B | ||
|
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
21 | $ 18.31 | 5.23 % | $ 410 M | ||
|
Invitae Corporation
NVTA
|
-10.7 | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-19.5 | $ 201.15 | 1.76 % | $ 19.8 B | ||
|
OPKO Health
OPK
|
25.9 | $ 1.2 | 0.84 % | $ 833 M |